Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Toshihiko Hashinaga is active.

Publication


Featured researches published by Toshihiko Hashinaga.


BMC Musculoskeletal Disorders | 2011

Hyperadiponectinemia enhances bone formation in mice

Yasuhiro Mitsui; Masafumi Gotoh; Nobuhiro Fukushima; Isao Shirachi; Shuichi Otabe; Xiaohong Yuan; Toshihiko Hashinaga; Nobuhiko Wada; Akiko Mitsui; Tatsuhiro Yoshida; Shiro Yoshida; Kentaro Yamada; Kensei Nagata

BackgroundThere is growing evidence that adiponectin, a physiologically active polypeptide secreted by adipocytes, controls not only adipose tissue but also bone metabolism. However, a role for adiponectin in bone development remains controversial.MethodsWe therefore investigated the endocrine effects of adiponectin on bone metabolism using 12-week-old male transgenic (Ad-Tg) mice with significant hyperadiponectinemia overexpressing human full-length adiponectin in the liver.ResultsIn Ad-Tg mice, the serum level of osteocalcin was significantly increased, but the levels of RANKL, osteoprotegerin, and TRAP5b were not. Bone mass was significantly greater in Ad-Tg mice with increased bone formation. In contrast, bone resorption parameters including the number of osteoclasts and eroded surface area did not differ between Ad-Tg and their littermates.ConclusionsThese findings demonstrate that hyperadiponectinemia enhances bone formation in mice.


PLOS ONE | 2017

Beneficial effects of metformin on energy metabolism and visceral fat volume through a possible mechanism of fatty acid oxidation in human subjects and rats

Ichiro Tokubuchi; Yuji Tajiri; Shimpei Iwata; Kento Hara; Nobuhiko Wada; Toshihiko Hashinaga; Hitomi Nakayama; Hiroharu Mifune; Kentaro Yamada; M. Faadiel Essop

Objective Metformin is known to have a beneficial effect on body weight and body composition, although the precise mechanism has not been elucidated yet. The aim of this study is to investigate the effects of metformin on energy metabolism and anthropometric factors in both human subjects and rats. Methods In human studies, metformin (1500mg/day) was administered to 23 healthy subjects and 18 patients with type 2 diabetes for 2 weeks. Metabolic parameters and energy metabolism were measured during a meal tolerance test in the morning before and after the treatment of metformin. In animal studies, 13 weeks old SD rats were fed 25–26 g of standard chow only during 12-hours dark phase with either treated by metformin (2.5mg/ml in drinking water) or not for 2 weeks, and metabolic parameters, anthropometric factors and energy metabolism together with expressions related to fat oxidation and adaptive thermogenesis were measured either in fasting or post-prandial state at 15 weeks old. Results Post-prandial plasma lactate concentration was significantly increased after the metformin treatment in both healthy subjects and diabetic patients. Although energy expenditure (EE) did not change, baseline respiratory quotient (RQ) was significantly decreased and post-prandial RQ was significantly increased vice versa following the metformin treatment in both groups. By the administration of metformin to SD rats for 2 weeks, plasma levels of lactate and pyruvate were significantly increased in both fasting and post-prandial states. RQ during a fasting state was significantly decreased in metformin-treated rats compared to controls with no effect on EE. Metformin treatment brought about a significant reduction of visceral fat mass compared to controls accompanied by an up-regulation of fat oxidation-related enzyme in the liver, UCP-1 in the brown adipose tissue and UCP-3 in the skeletal muscle. Conclusion From the results obtained, beneficial effects of metformin on visceral fat reduction has been demonstrated probably through a mechanism for a potential shift of fuel resource into fat oxidation and an upregulation of adaptive thermogenesis independent of an anorexigenic effect of this drug.


PLOS ONE | 2013

Selective Modulation of Wnt Ligands and Their Receptors in Adipose Tissue by Chronic Hyperadiponectinemia

Nobuhiko Wada; Toshihiko Hashinaga; Shuichi Otabe; Xiaohong Yuan; Yayoi Kurita; Satomi Kakino; Tsuyoshi Ohoki; Hitomi Nakayama; Tomoka Fukutani; Yuji Tajiri; Kentaro Yamada

Background Adiponectin-transgenic mice had many small adipocytes in both subcutaneous and visceral adipose tissues, and showed higher sensitivity to insulin, longer life span, and reduced chronic inflammation. We hypothesized that adiponectin regulates Wnt signaling in adipocytes and thereby modulates adipocyte proliferation and chronic inflammation in adipose tissue. Materials and Methods We examined the expression of all Wnt ligands and their receptors and the activity of Wnt signaling pathways in visceral adipose tissue from wild-type mice and two lines of adiponectin-transgenic mice. The effects of adiponectin were also investigated in cultured 3T3-L1 cells. Results The Wnt5b, Wnt6, Frizzled 6 (Fzd6), and Fzd9 genes were up-regulated in both lines of transgenic mice, whereas Wnt1, Wnt2, Wnt5a, Wnt9b, Wnt10b, Wnt11, Fzd1, Fzd2, Fzd4, Fzd7, and the Fzd coreceptor low-density-lipoprotein receptor-related protein 6 (Lrp6) were reduced. There was no difference in total β-catenin levels in whole-cell extracts, non-phospho-β-catenin levels in nuclear extracts, or mRNA levels of β-catenin target genes, indicating that hyperadiponectinemia did not affect canonical Wnt signaling. In contrast, phosphorylated calcium/calmodulin-dependent kinase II (p-CaMKII) and phosphorylated Jun N-terminal kinase (p-JNK) were markedly reduced in adipose tissue from the transgenic mice. The adipose tissue of the transgenic mice consisted of many small cells and had increased expression of adiponectin, whereas cyclooxygenase-2 expression was reduced. Wnt5b expression was elevated in preadipocytes of the transgenic mice and decreased in diet-induced obese mice, suggesting a role in adipocyte differentiation. Some Wnt genes, Fzd genes, and p-CaMKII protein were down-regulated in 3T3-L1 cells cultured with a high concentration of adiponectin. Conclusion Chronic hyperadiponectinemia selectively modulated the expression of Wnt ligands, Fzd receptors and LRP coreceptors accompanied by the inhibition of the Wnt/Ca2+ and JNK signaling pathways, which may be involved in the altered adipocyte cellularity, endogenous adiponectin production, and anti-inflammatory action induced by hyperadiponectinemia.


Hormone and Metabolic Research | 2018

Pivotal Role of TNF-α in the Development and Progression of Nonalcoholic Fatty Liver Disease in a Murine Model

Satomi Kakino; Tsuyoshi Ohki; Hitomi Nakayama; Xiahong Yuan; Shuichi Otabe; Toshihiko Hashinaga; Nobuhiko Wada; Yayoi Kurita; Kayo Tanaka; Kento Hara; Eri Soejima; Yuji Tajiri; Kentaro Yamada

Previously, we have shown that the adipocyte-specific nuclear form of sterol regulatory element-binding protein-1c (nSREBP-1c) transgenic mice spontaneously developed hepatic lesions that are similar to those of human nonalcoholic steatohepatitis (NASH) with a concomitant elevation of plasma TNF-α. In this study, we analyzed the role of TNF-α in the progression of nonalcoholic fatty liver disease (NAFLD). We established a Tnf knockout nSREBP-1c transgenic mouse line. Glucose tolerance and liver histology were examined at the age of 20 weeks. The gene expression and protein levels were assessed by quantitative RT-PCR and Western blot, respectively. The Tnf knockout improved glucose tolerance and significantly reduced the prevalence of hepatic steatosis (20% vs. 100%, p<0.0001) and fibrosis (15% vs. 65%, p=0.0057). The expressions of Acaca, Scd1, Mcp1, Tgfb1, Col1a1, and Timp1 were increased in the liver from the original nSREBP-1c transgenic mice. However, gene upregulation was reduced in the livers from the Tnf(-/-) nSREBP-1c transgenic mice. Furthermore, the hepatic levels of TIMP1 protein were increased in the original nSREBP-1c transgenic mice but not in Tnf(-/-) nSREBP-1c transgenic mice. To assess the direct effect of TNF-α on the expression of the genes, we cultured primary hepatocytes in the presence of TNF-α and found that TNF-α increased the expression of Mcp1, Tgfb1, and Timp1 in hepatocytes. These observations indicate that TNF-α plays a pivotal role in the development of NAFLD and progression to NASH through upregulating key molecules associated with lipid metabolism, inflammatory cytokines, and fibrosis in the liver.


American Journal of Physiology-endocrinology and Metabolism | 2007

Overexpression of human adiponectin in transgenic mice results in suppression of fat accumulation and prevention of premature death by high-calorie diet

Shuichi Otabe; Xiaohong Yuan; Tomoka Fukutani; Nobuhiko Wada; Toshihiko Hashinaga; Hitomi Nakayama; Naotoshi Hirota; Kentaro Yamada


Metabolism-clinical and Experimental | 2007

Transgenic mice expressing nuclear sterol regulatory element-binding protein 1c in adipose tissue exhibit liver histology similar to nonalcoholic steatohepatitis.

Hitomi Nakayama; Shuichi Otabe; Takato Ueno; Naotoshi Hirota; Xiaohong Yuan; Tomoka Fukutani; Toshihiko Hashinaga; Nobuhiko Wada; Kentaro Yamada


Metabolism-clinical and Experimental | 2009

Effects of adiponectin transgenic expression in liver of nonalcoholic steatohepatitis model mice

Hitomi Nakayama; Shuichi Otabe; Xiaohong Yuan; Takato Ueno; Naotoshi Hirota; Tomoka Fukutani; Nobuhiko Wada; Toshihiko Hashinaga; Kentaro Yamada


Endocrine Journal | 2012

Modulation by adiponectin of circadian clock rhythmicity in model mice for metabolic syndrome

Toshihiko Hashinaga; Nobuhiko Wada; Shuichi Otabe; Xiaohong Yuan; Yayoi Kurita; Satomi Kakino; Kayo Tanaka; Takahiro Sato; Tsuyoshi Ohki; Hitomi Nakayama; Tomoka Egashira; Yuji Tajiri; Kentaro Yamada


Acta Diabetologica | 2010

Excessive maternal transmission of diabetes in Japanese families with young-onset type 2 diabetes and insulin secretion defect according to clinical features

Shuichi Otabe; Hitomi Nakayama; Tomoka Fukutani; Xiaohong Yuan; Nobuhiko Wada; Toshihiko Hashinaga; Akiko Mitsui; Tomoko Kato; Chizuko Inada; Yuji Tajiri; Kentaro Yamada


Acta Diabetologica | 2007

Clinical and genetic features of childhood-onset Type 2 diabetes in Japan

Shuichi Otabe; Hitomi Nakayama; Tomoka Fukutani; Xiaohong Yuan; Nobuhiko Wada; Toshihiko Hashinaga; Tomoko Kato; Chizuko Inada; Kentaro Yamada

Collaboration


Dive into the Toshihiko Hashinaga's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge